Criteria to qualify for study: Drug used in study:
  • Roll over study for Hemref34 patients

Hemref 45 IPI-145-23 Infinity Pharmaceuticals Inc Research

A Long-term, Continued Treatment and Follow-up Study in Subjects with Hematologic Malignancies Treate with Duvelisib (IPI-145)